Clinical trial · Observational
Ex Vivo Drug Response Profiling and Outcome Prediction in Lung Adenocarcinoma
NCT07636252CI-TRIAL-00115651recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This observational study evaluates if ex-vivo lung cancer drug sensitivity testing results correlate with the driver mutations found by genetic sequencing and if it can predict treatment response.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Adenocarcinoma | Lung Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Malignant Pleural Effusions (Mpe) | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Non-Interventional Study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with diagnosis of a Lung adenocarcinoma with the need of pleural drainage due to MPE
- interventionNames
- Other: Non-Interventional Study
Primary outcomes (1)
- measure
- Statistically significant correlation between patients' drug response by ex-vivo drug profiling and expected drug sensitivity according to genetic sequencing
- timeFrame
- From enrollment until results of clinical genetic sequencing and drug sensitivity testing are obtained (within 3 weeks).
- description
- Ex-vivo drug sensitivity categorizes drugs as sensitive/not sensitive. Results will be compared with the expected sensitivity of drugs according to the driver mutation found be genetic sequencing. For example, in EGFR-driven lung cancer, the tumor cells are expected to be more sensitive to EGFR-targeting drugs than to ALK-targeting drugs.
Secondary outcomes (1)
- measure
- Accuracy of patients' drug response prediction by ex-vivo drug profiling
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Presence of pleural effusion in patient with a diagnosis of a lung cancer or suspected to be diagnosed with lung cancer according to their CT imaging, who are in need for pleural effusion drainage due to shortness of breath, and are willing to donate effusion for ex-vivo drug sensitivity testing. * Patient's written informed consent present. * Ability to understand the nature of the trial and the trial related procedures and to comply with them. Exclusion Criteria: * negative cytology for malignancy in the last 6 months
References
Publications (0)
Data not yet available
No reference posted for this study.